ArticleEpidemiology and infection2024
A scoping review on the community dividend resulting from testing and treating hepatitis C infection in people living in detention.
Article in Epidemiology and infection, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A scoping review was conducted to map out sources, types, characteristics of evidence that substantiate the existence of a community dividend arising from testing and treating hepatitis C virus (HCV) infection in people living in detention - where community dividend is defined as the benefit of prison-related intervention for general population health. Joanna Briggs Institute methodology guidance was used. Literature search was done in EMBASE, Scopus, ASSIA, UWE library, CINAHL Plus, and Medline to find studies published in any country, any language between January 1991 and June 2022. PRISMA ScR flow chart mapped out the number of records identified, included, and reasons for exclusion. Data were extracted and charted in Excel. The findings were systematically reported by charting table headings then synthesized in the discussion. Quality assessment was carried out. The descriptive analysis demonstrated economic, clinical, and epidemiological domains to the community dividend in long-term health expenditure savings, reduction in HCV-related disease sequelae, increase in survival, improvement in quality of life, and reduction in infection transmission, most of which are realized in the community following release. Therefore, targeting marginalized populations affected by HCV could expedite the elimination effort, reduce inequalities, and have a positive impact on the wider population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.